Allegro Ophthalmics LLC Begins Phase 2 Clinical Trial Of Luminate® (ALG-1001) For The Treatment Of Diabetic Macular Edema

CHICAGO--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vitreo-retinal diseases, today announced that it is enrolling patients in a Phase 2 trial that will evaluate the safety and efficacy of Luminate®, previously known as ALG-1001, in patients with diabetic macular edema (DME).

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC